Ribi, Karin
,
Luo, Weixiu
Colleoni, Marco
Karlsson, Per
Chirgwin, Jacquie
Aebi, Stefan
Jerusalem, Guy
Neven, Patrick
Di Lauro, Vincenzo
Gomez, Henry L.
Ruhstaller, Thomas
Abdi, Ehtesham
Biganzoli, Laura
Müller, Bettina
Barbeaux, Annelore
Graas, Marie-Pascale
Rabaglio, Manuela
Francis, Prudence A.
Foukakis, Theodoros
Pagani, Olivia
Graiff, Claudio
Vorobiof, Daniel
Maibach, Rudolf
Di Leo, Angelo
Gelber, Richard D.
Goldhirsch, Aron
Coates, Alan S.
Regan, Meredith M.
Bernhard, Jürg
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
Article History
Received: 30 August 2018
Revised: 28 February 2019
Accepted: 7 March 2019
First Online: 10 April 2019
Change Date: 16 January 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing interests
: Dr Colleoni reports advisory board fees from AstraZeneca, Pierre Fabre, Pfizer, OBI Pharma, Puma Biotechnology, Celldex; and honoraria from Novartis. Dr Karlsson reports advisory board fees from Novartis. Dr Jerusalem reports grants from Novartis, Roche, Amgen, BMS, and MSD; personal fees from Novartis, Roche, Lilly, Celgene, Amgen, BMS, Pfizer, Puma, Daiichi-Sankyo, MSD, and AstraZeneca; and non-financial support from Novartis, Roche, Lilly, BMS, and AstraZeneca. Dr Ruhstaller reports travel grants from Roche and Amgen; and advisory board fees from Novartis, Roche, AstraZeneca, and Lilly; and honoraria from Pfizer. Dr Francis reports personal fees from AstraZeneca and Novartis; and non-financial support from Pfizer: Dr Foukakis reports an institutional grant from Pfizer; and personal fees from Novartis and UpToDate. Dr Leo reports grants from AstraZeneca, Pierre Fabre, and Pfizer; and personal fees from AstraZeneca, Bayer, Celgene, Daichii-Sankyo, Eisai, Genomic Health, Ipsen, Lilly, Novartis, Pierre Fabre, Pfizer, and Roche. Dr Gelber reports institution fees from Novartis, Pfizer, AstraZeneca, Merck, Celgene, Ferring, Roche, and Ipsen. Dr Goldhirsch reports that the institute received a per-patient fee from the IBCSG for trial conduct. Dr Regan reports grants from International Breast Cancer Study Group, during the conduct of the study; grants from Novartis, grants from Pfizer, grants from Ipsen, outside the submitted work. The remaining authors declare no competing interests.
: Ethics committees and appropriate national health authorities from each centre approved the protocol, including this sub-study, and all patients provided written informed consent as part of the informed consent for the main trial. The study was performed in accordance with the Declaration of Helsinki.
: The data on which these analyses are based forms part of the clinical trials database of the International Breast Cancer Study Group, and as such is available for use on application in accordance with IBCSG data sharing policy.
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).